Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colesevelam and Metformin in Type 2 Diabetes and Pre-diabetes
NCT00570739Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2007
- Primary completion
- Apr 2009
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of colesevelam in type 2 diabetes mellitus (T2DM), prediabetes and hypercholesterolemia (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Percent Change of Hemoglobin A1C From Baseline at 16 weeks and Percent Change in Low Density Lipoprotein-Cholesterol at 16 weeks. Started Nov 2007; status: completed.
02
Drugs
colesevelam
03
Conditions
type 2 diabetes mellitus (T2DM)prediabeteshypercholesterolemia
Beyond the preview
Go deeper on NCT00570739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570739.